BOISE, ID - Albertsons® Companies, Inc. reported results for the fourth quarter of fiscal 2025 and full year fiscal 2025, which ended Feb. 28, 2026 and included 13 and 53 weeks, respectively.
In a LinkedIn post accompanying the announcement, CEO Susan Morris highlighted the company’s disciplined execution and thanked associates for their role in delivering results.
Fourth Quarter of Fiscal 2025 Highlights
- Identical sales increased 0.7%
- Digital sales increased 16%
- Loyalty members increased 12% to 51.2 million
- Net loss of $(481) million, or $(0.94) per share, inclusive of the $600 million charge, net of tax, or $(1.18) per share, related to the Opioid
- Settlement Framework (as defined herein)
- Adjusted net income of $252 million, or $0.48 per share
- Adjusted EBITDA of $903 million
Fiscal 2025 Highlights
- Identical sales increased 2.0%
- Digital sales increased 21%
- Net income of $217 million, or $0.40 per share
- Adjusted net income of $1,209 million, or $2.18 per share
- Adjusted EBITDA of $3,902 million
"Fiscal 2025 was a year of disciplined execution and resilience, as we closed the year with a solid fourth quarter that delivered strong Adjusted EBITDA despite meaningful top-line pharmacy-related headwinds," said Susan Morris, CEO of Albertsons Companies, in the recent release.
Morris continued, "Across the full year, we remained focused on building a stronger foundation for the future, including investing in our customer value proposition, advancing digital and loyalty, and strengthening the capabilities that support sustainable, long-term growth. As we enter fiscal 2026, we are building on this foundation by scaling our productivity engine and positioning the company to deliver earnings growth, strong cash flow, and long-term shareholder returns."
Fourth Quarter of Fiscal 2025 Results
Net sales and other revenue was $20.3 billion for the 13 weeks ended Feb. 28, 2026 ("fourth quarter of fiscal 2025") compared to $18.8 billion during the 12 weeks ended Feb. 22, 2025 ("fourth quarter of fiscal 2024"). The increase included approximately $1.4 billion incremental net sales related to the extra week in the fourth quarter of fiscal 2025. Identical sales increased 0.7%, primarily driven by pharmacy sales, which were impacted more than expected by the pricing headwinds related to the Inflation Reduction Act ("IRA") and a mix shift within the broader pharmacy industry. The Company also continued to grow its digital sales with a 16% sales increase during the fourth quarter of fiscal 2025. These increases in Net sales and other revenue were partially offset by a net reduction in sales driven by store closures since the fourth quarter of fiscal 2024.
See the full result here.
